bioRxivImmunologyPreprint
Microtubule anchoring and coupling of CD20 to the RhoA/Rock1 pathway
Kathrin KläseneriD, Cindy Eunhee LeeiD, Julian BenderiD, Angela NaumanniD, Lena ReimanniD, Geoffroy AndrieuxiD, Claudio MussolinoiD, Nadja HerrmanniD, Roland NitschkeiD, Reinhard Edmund VolliD, Bettina WarscheidiD, Klaus WarnatziD, Michael G. RethiD
Abstract
CD20 is a B cell-specific four-helix transmembrane protein and a prominent target of therapeutic anti-CD20 antibodies. CD20 is localized within a membrane nanocluster harboring the IgD class B cell antigen receptor (IgD-BCR) where it functions as a gatekeeper for the resting state of naive B lymphocytes. How CD20 exerts its gatekeeper function is not yet known. Using Ramos and human peripheral blood B cells, we show here that the serine/threonine kinase PKC{delta}, constitutively phosphorylates serine residues at the cytosolic tails of CD20. The phosphorylated CD20 becomes a target for 14-3-3 adaptor proteins that link CD20 to the RhoA GDP/GTP exchange factor GEF-H1 and the microtubule (MT) network controlling the stability of the IgD-BCR nanocluster. The binding of anti-CD20 antibodies results in MT disassembly and the replacement of the GEF-H1/CD20 complex by a RhoA-GTP/ROCK1/CD20 complex which drives actomyosin contractility. Our study suggests that CD20 not only maintains the resting state, but also orchestrates the MT/actin switch in active B lymphocytes. This could have implications for treatment with anti-CD20 antibodies and may help to optimize therapeutic protocols. Graphic abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=84 SRC="FIGDIR/small/656301v2_ufig1.gif" ALT="Figure 1"> View larger version (23K): org.highwire.dtl.DTLVardef@1cfe15aorg.highwire.dtl.DTLVardef@d3ee14org.highwire.dtl.DTLVardef@1b375eforg.highwire.dtl.DTLVardef@103c9dd_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: proteomics
- research focus: cell signaling & trafficking
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- CD20 as a gatekeeper of the resting stage of human B cells
K. Klasener, J. Jellusova, … M. Reth·bioRxiv·Jul 31, 2020
- Imaging the mechanisms of anti-CD20 therapy in vivo uncovers spatiotemporal bottlenecks in antibody-dependent phagocytosis
C. L. Grandjean, Z. Garcia, … P. Bousso·bioRxiv·May 26, 2020
- Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression
Oanh T. P. Nguyen, Sandra Lara, … Sandra Kleinau·Frontiers in ImmunologyPeer-reviewed·Dec 6, 2024
- Diacylglycerol kinase zeta dictates CD40-mediated immune synapse formation, mTORC1 signaling and plasma cell fate in B lymphocytes
Ana Fernández-Barrecheguren, Adrián Fernández-Rego, … Yolanda R. Carrasco·Science SignalingPeer-reviewed·Jun 23, 2026
- IgG surface mobility promotes antibody-dependent cellular phagocytosis by Syk and Arp2/3 mediated reorganization of Fcγ receptors in macrophages.
S. Jo, N. M. Cronin, … A. D. Hoppe·bioRxiv·Jul 12, 2021
- Targeting the mTORC2 signaling complex in B cell malignancies.
W. Liao, G. Jordaan, … S. Sharma·bioRxiv·Mar 5, 2019